我的生活+的主要目标之一是帮助人们预防新的HIV和其他STI,丙型肝炎和结核病病历的产生。

该应用程序有助于建立医生和HIV感染者之间的匿名沟通。 它可以让您创建简单易行的服药时间表,并设置隐藏和个性化的提醒。

返回
11 一月 2019, 13:53
1251

MSD could not challenge Gilead’s rights to sofosbuvir in court

MSD could not challenge Gilead’s rights to sofosbuvir in court - 图片 1

The American pharmaceutical company Merck (outside the US and Canada - MSD) was unable to appeal against patents of Gilead for the drug for the treatment of hepatitis C sofosbuvir. The US Supreme Court rejected the appeal of an organization demanding compensation for violating its rights in the amount of $ 200 million.

It was this amount in March 2016 that the Californian jury ordered to pay MSD. Later, however, this decision was changed because it became known that the claimant company used Pharmasset company acquired Gilead in 2011 when registering patents.

At the beginning of this week, a final decision was made on this case - the Supreme Court rejected the claims of MSD against Gilead.

It is important to note that on the same day, January 7, the court also rejected the appeal of Gilead in the case of accusing the company of using low-quality raw materials in the production of expensive drugs for the treatment of HIV infection Emtriva, Truvada and Atripla.

Recall the criminal case against the world's largest manufacturer of medicines for the treatment of HIV infection and hepatitis C was launched in 2015 in connection with the testimony of its former employees about the supply of cheap substances from China under the guise of registered South Korean.

在社交媒体上分享